Ask AI
ProCE Banner Activity

INAVO120: OS From Phase III Study of 1L Inavolisib/PBO + Palbociclib + Fulvestrant in PIK3CA-Mutated, HR+/HER2-, Endocrine-Resistant Advanced Breast Cancer 

Conference Coverage
Slideset

Final overall survival analysis results from the randomized phase III INAVO120 study demonstrated a 7-month improvement and a continued progression-free survival improvement with inavolisib + palbociclib + fulvestrant vs placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR+/HER2-, endocrine-resistant advanced breast cancer.

Released: June 04, 2025

Expiration: December 03, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.